Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWIVM3)

Drug Name

PF-06454589 Drug Info

Synonyms

compound 28 [PMID: 25353650]

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Leucine-rich repeat kinase 2 (LRRK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DNL151	DMZT89C	Parkinson disease	8A00.0	Phase 1	[3]
DNL201	DMFEORD	Parkinson disease	8A00.0	Phase 1	[3]
BIIB094	DMLUO5K	Parkinson disease	8A00.0	Phase 1	[4]
Pyrrolo-pyridine derivative 2	DMVNY5I	N. A.	N. A.	Patented	[5]
Bidentate ligands of Markush derivative 2	DM2QNMC	N. A.	N. A.	Patented	[5]
Oxindole derivative 3	DM0ENF3	N. A.	N. A.	Patented	[5]
Aminopyridine derivative 3	DMSLJE8	N. A.	N. A.	Patented	[5]
Fused thiophene derivative 1	DMV7IX4	N. A.	N. A.	Patented	[5]
Oxindole derivative 4	DM3U58I	N. A.	N. A.	Patented	[5]
Bidentate ligands of Markush derivative 1	DMB08D3	N. A.	N. A.	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leucine-rich repeat kinase 2 (LRRK2)	TTK0FEA	LRRK2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8295).
2	Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015 Jan 8;58(1):419-32.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of Ionis
5	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.